Cytosorbents Co. to Post Q3 2022 Earnings of ($0.13) Per Share, Jefferies Financial Group Forecasts (NASDAQ:CTSO)

Cytosorbents Co. (NASDAQ:CTSOGet Rating) – Research analysts at Jefferies Financial Group issued their Q3 2022 earnings per share estimates for Cytosorbents in a note issued to investors on Tuesday, August 2nd. Jefferies Financial Group analyst Z. Weiner forecasts that the medical research company will post earnings of ($0.13) per share for the quarter. The consensus estimate for Cytosorbents’ current full-year earnings is ($0.69) per share. Jefferies Financial Group also issued estimates for Cytosorbents’ Q4 2022 earnings at ($0.11) EPS, FY2022 earnings at ($0.69) EPS, FY2023 earnings at ($0.14) EPS, FY2024 earnings at $0.25 EPS and FY2025 earnings at $0.47 EPS.

Cytosorbents (NASDAQ:CTSOGet Rating) last announced its quarterly earnings results on Tuesday, May 3rd. The medical research company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.06). The company had revenue of $8.69 million during the quarter, compared to analysts’ expectations of $9.72 million. Cytosorbents had a negative net margin of 94.25% and a negative return on equity of 60.22%. During the same quarter last year, the firm posted ($0.10) earnings per share.

Separately, B. Riley reduced their price target on Cytosorbents from $7.00 to $6.00 in a research report on Wednesday, May 4th.

Cytosorbents Stock Performance

Shares of NASDAQ CTSO opened at $2.10 on Friday. The stock has a market cap of $91.48 million, a PE ratio of -2.56 and a beta of 0.37. Cytosorbents has a fifty-two week low of $1.69 and a fifty-two week high of $9.80. The stock has a fifty day moving average of $2.14 and a 200-day moving average of $2.74.

Hedge Funds Weigh In On Cytosorbents

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CTSO. CM Management LLC boosted its holdings in shares of Cytosorbents by 71.4% in the 4th quarter. CM Management LLC now owns 300,000 shares of the medical research company’s stock worth $1,257,000 after purchasing an additional 125,000 shares in the last quarter. Royce & Associates LP boosted its holdings in shares of Cytosorbents by 28.1% in the 4th quarter. Royce & Associates LP now owns 251,000 shares of the medical research company’s stock worth $1,052,000 after purchasing an additional 55,000 shares in the last quarter. Skylands Capital LLC boosted its holdings in shares of Cytosorbents by 5.9% in the 4th quarter. Skylands Capital LLC now owns 1,946,374 shares of the medical research company’s stock worth $8,155,000 after purchasing an additional 108,833 shares in the last quarter. Raymond James Financial Services Advisors Inc. purchased a new position in shares of Cytosorbents in the 4th quarter worth about $199,000. Finally, Paradigm Financial Partners LLC purchased a new position in shares of Cytosorbents in the 4th quarter worth about $159,000. 40.98% of the stock is currently owned by hedge funds and other institutional investors.

About Cytosorbents

(Get Rating)

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications of cardiopulmonary bypass surgery, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant.

See Also

Earnings History and Estimates for Cytosorbents (NASDAQ:CTSO)

Want More Great Investing Ideas?

Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.